# SURPASS-2: Tirzepatide vs Semaglutide | GLP1Nerds Canonical: https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/ Published: 2026-10-25 Updated: 2026-10-25 SURPASS-2 favored tirzepatide against semaglutide 1 mg in type 2 diabetes. That dose and population define the comparison. [Research](https://glp1nerds.com/research/)/Medications Medications # Tirzepatide vs semaglutide in diabetes: SURPASS-2 SURPASS-2 favored tirzepatide against semaglutide 1 mg in type 2 diabetes. That dose and population define the comparison. OC[Owen Calder](https://glp1nerds.com/authors/owen-calder/)Founding Editor · Updated October 2026 Editorial analysis · Not a clinical consultation ![SURPASS-2: two cards name Tirzepatide and Semaglutide.](https://glp1nerds.com/assets/editorial/tirzepatide-semaglutide-surpass2.svg) Conceptual comparator diagram, not an efficacy chart. See the article for the exact study population, doses, outcomes and limitations. ## What to know - SURPASS-2 favored tirzepatide against semaglutide 1 mg in type 2 diabetes. That dose and population define the comparison. - The studied population, comparator and follow-up determine how far the result travels. - Use the findings to frame a discussion, rather than predict an individual result. ## The comparator is the headline SURPASS-2 found greater average HbA1c reductions with tirzepatide than with semaglutide 1 mg in adults with type 2 diabetes taking metformin. That is an important direct comparison. It is not interchangeable with the later obesity comparison commonly discussed online, and it does not mean tirzepatide was tested against every current semaglutide dose. A useful headline includes the 1 mg comparator instead of hiding it in a footnote. The purpose of reading the study closely is to understand the actual choice being tested, then decide with a clinician whether that choice resembles the one in front of you.[\[1\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-1) For the connected question, read [the separate obesity head-to-head trial](https://glp1nerds.com/research/semaglutide-vs-tirzepatide/). ## A forty-week diabetes experiment The trial randomized 1,879 participants to weekly tirzepatide at 5, 10 or 15 mg, or weekly semaglutide at 1 mg, with 40 weeks of follow-up. Participants had type 2 diabetes inadequately controlled with metformin. Treatment was open label. The study therefore offers a cleaner comparison than matching separate marketing claims, because the groups were assembled within the same protocol. Nevertheless, the result remains specific to diabetes, background treatment and the trial period. Someone without diabetes considering obesity care has a different clinical question, even when the ingredient names look familiar. Similar packaging does not make two populations or indications equivalent.[\[1\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-1) ## Read the HbA1c difference in percentage points Average HbA1c reductions were 2.01, 2.24 and 2.30 percentage points in the three tirzepatide groups, compared with 1.86 points in the semaglutide group. All three tirzepatide doses met the trial's superiority criterion for this measure. Notice that both treatments lowered HbA1c substantially in the study. Superiority describes an additional average reduction relative to an active treatment; it does not mean the comparator failed. It also does not translate directly into a percentage reduction in complications. When a number moves from a scientific paper to a consumer article, keeping the units and the active comparator attached prevents an exaggerated impression of benefit.[\[1\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-1) ## Weight matters without becoming the only endpoint The trial also favored tirzepatide on body weight. That finding can matter to someone managing diabetes, but the full decision still includes glucose goals, other medicines, clinical history and tolerability. It would be misleading to lift a weight figure from a diabetes trial and present it as the expected outcome of a retail obesity program. The trial measures the medicines within a research setting, not a particular clinic's coaching quality or a pharmacy's reliability. Nor does an average weight change identify which part of a person's weight change would be fat, fluid or lean tissue. Those are separate questions requiring their own measurements.[\[1\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-1) For the connected question, read [what body-composition measurements show](https://glp1nerds.com/research/lean-mass-glp1/). ## Why SUSTAIN FORTE belongs beside this result SUSTAIN FORTE separately randomized semaglutide 2 mg against 1 mg in adults with type 2 diabetes and found an additional average glycemic benefit with the higher dose. That result explains why the SURPASS-2 comparator boundary matters. It does not supply a missing randomized comparison between semaglutide 2 mg and tirzepatide. Subtracting an effect from one trial from an effect in another can look precise while ignoring differences in participants, background medicines and statistical analysis. The sensible conclusion is that dose can affect outcomes. The unsound conclusion is that a reader can reconstruct an unperformed head-to-head trial with a calculator.[\[2\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-2) ## Do not confuse the obesity evidence SURPASS-2 is part of the diabetes development program. Our separate semaglutide versus tirzepatide article discusses the obesity comparison and its own formulations, doses and follow-up. Neither study needs to be stretched to answer the other's question. If a clinician is considering treatment for diabetes, the glucose endpoint and diabetes population are directly relevant. If someone is considering chronic weight management without diabetes, the obesity evidence has a closer population match. A brand name, ingredient name and indication are three connected but distinct pieces of information. Clarifying all three is more useful than asking which molecule wins in the abstract.[\[1\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-1) ## Averages do not decide the next dose The dose groups make it tempting to read the table as a ladder that everyone should climb. That is not what randomization establishes. The study assigned treatment strategies under a protocol; a real prescription requires an assessment of response, tolerability and current product instructions. Current Mounjaro labeling includes precautions, contraindications and clinical monitoring considerations that cannot be replaced by the efficacy ranking. In particular, treatment alongside insulin or a sulfonylurea changes the hypoglycemia discussion. This article reports the study's assigned doses as evidence context. It is not a reason to increase, combine or switch prescription treatment independently.[\[3\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-3) For the connected question, read [our Sesame access review](https://glp1nerds.com/reviews/sesame/). ## Gastrointestinal effects deserve a practical plan Nausea, diarrhea and vomiting were among the commonly reported problems in SURPASS-2. A reader should resist two opposite mistakes: assuming these effects invalidate the glucose result, or dismissing them because the trial's averages look impressive. A medicine that is unsuitable or intolerable for a particular person can be the wrong practical choice despite an average advantage. Before paying a clinic, ask who evaluates symptoms, how nonurgent concerns are handled and how care continues if the original plan changes. Those questions evaluate the service around treatment; they cannot be answered from the drug trial itself.[\[1\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-1) [\[3\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-3) ## Glucose superiority is not an event trial SURPASS-2 was not designed to establish superiority for heart attacks, stroke, kidney failure or mortality. Current indications may incorporate evidence obtained after this study, and should be checked in the current product label. That distinction protects against an easy shortcut: assuming the treatment with the larger HbA1c reduction must prevent more of every complication. Surrogate endpoints can be useful without being identical to clinical events. The same caution applies to consumer claims about longevity. A 40-week diabetes comparison cannot show how many extra years someone will live, and no legitimate interpretation of the trial requires making that claim.[\[1\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-1) [\[3\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-3) ## The decision worth taking to an appointment SURPASS-2 is a strong reason to take tirzepatide's comparative diabetes efficacy seriously, with semaglutide 1 mg named explicitly as the comparator. Eli Lilly funded the trial. The next useful step is a conversation about the person's actual treatment goal, current formulation, other medication, contraindications, coverage and ability to maintain follow-up. A lower price from a different service does not prove an equivalent care pathway, and a stronger trial average does not guarantee a particular response. Read this trial as a defined comparison, then use the wider evidence and current prescribing information to answer the clinical question it leaves open.[\[1\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-1) [\[3\]](https://glp1nerds.com/research/tirzepatide-semaglutide-surpass2/#reference-3) For a separate look at ongoing care options, read [our Ro and Form Health comparison](https://glp1nerds.com/compare/ro-vs-form-health/). For the related study question, read [SURPASS-1: strong glucose control is not drug-free remission](https://glp1nerds.com/research/tirzepatide-monotherapy-surpass1/). ## Put the evidence in context [the separate obesity head-to-head trial](https://glp1nerds.com/research/semaglutide-vs-tirzepatide/) [what body-composition measurements show](https://glp1nerds.com/research/lean-mass-glp1/) [our Sesame access review](https://glp1nerds.com/reviews/sesame/) ## Sources - [Frías et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021) (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/34170647/) - [Frías et al. SUSTAIN FORTE randomized trial (2021) (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/34293304/) - Mounjaro current US prescribing information (opens in a new tab) Research describes groups and specific study conditions. Your medical history, symptoms and treatment decisions require advice from your own qualified clinician. ## Keep exploring. [Research library](https://glp1nerds.com/research/) Medications ### [Semaglutide vs tirzepatide: what the direct trial answers](https://glp1nerds.com/research/semaglutide-vs-tirzepatide/) The strongest comparison concerns specific injectable doses, a defined population and 72 weeks of follow-up. Owen Calder Body composition ### [Lean mass during GLP-1 treatment: read beyond the headline](https://glp1nerds.com/research/lean-mass-glp1/) DEXA lean tissue, skeletal muscle and physical ability answer different questions. Owen Calder Medications ### [Semaglutide with type 2 diabetes: why STEP 2 needs its own comparison](https://glp1nerds.com/research/semaglutide-type2-diabetes-step2/) STEP 2 studied adults with type 2 diabetes and excess weight; its population, weekly doses and 68-week outcomes matter more than a borrowed headline. Owen Calder